Hair Growth & Loss Patents: Leaders, Trends & White Space 2026
Hair growth and hair loss treatment patents: who holds the ground and where it is still open
Filing has cooled from its 2017 peak of 980 records but 2021→2024 still shows a -25% pullback rather than a plateau, so the near-term trend is genuinely down, not just an artefact of publication lag. Filings peaked at 980 in 2017 and have since eased; the 2021 to 2024 window shows a -25% contraction (835 to 626), which is the clearest complete-year signal this dataset offers. 2025 and 2026 figures should be read as still filling in given publication lag, not as confirmation the decline is accelerating.
- 1VERTEX PHARMACEUTICALS INC2.9%
- 2AMGEN INC2.3%
- 3BOARD OF RGT THE UNIV OF TEXAS SYST2.2%
- 4TAKEDA PHARMA CO LTD2.1%
- 5MEDIVATION TECHNOLOGIES INC1.5%
See the full hair growth and hair loss treatment analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on hair growth and hair loss patents
Who holds the most patents in hair growth and hair loss treatment?
The ranked leader in this dataset holds 506 records, well ahead of the fifth-ranked assignee at 258 and the tenth at 221. That said, the top 5 assignees combined account for only 11.0% of all 17,536 records in scope, and the top 10 reach 17.7%, so no single company controls the field. The remaining filings are spread across a long tail of the 100 ranked assignees plus entities outside that ranking, which matters for anyone assuming a small set of blocking portfolios.
Is hair loss treatment patent filing growing or slowing down?
Filing peaked in 2017 at 980 records and has since declined; the most reliable complete-year comparison, 2021 to 2024, shows a -25% drop from 835 to 626. That is a genuine pullback rather than an artefact of recent data being incomplete. The 2025 and 2026 figures in any chart should be read cautiously, since publication typically lags filing by around 18 months and those years will fill in as more records publish.
What patent classes cover topical minoxidil and similar treatments?
The bulk of activity sits in A61K, medicinal preparations, which touches 81.8% of the 17,536 records in scope, and A61P, therapeutic activity of compounds, at 51.4%. Beneath those, C07D (heterocyclic compounds, 29.8%) and C07K (peptides and proteins, 18.5%) show meaningful molecular and biologic claim activity. A61Q, the cosmetics-use class, covers only 4.9% of records, which is thin relative to how much commercial activity in hair care sits on cosmetic rather than therapeutic framing.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Hair Growth and Hair Loss Treatment covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.